Johnson & Johnson (NYSE:JNJ – Get Free Report) shares rose 1.1% during mid-day trading on Friday . The company traded as high as $161.69 and last traded at $161.39. Approximately 3,607,042 shares changed hands during trading, a decline of 59% from the average daily volume of 8,790,578 shares. The stock had previously closed at $159.68.
Analyst Ratings Changes
Several analysts have weighed in on the stock. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Stifel Nicolaus reduced their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Guggenheim raised their price target on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.
View Our Latest Stock Report on JNJ
Johnson & Johnson Trading Up 2.0 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.29 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.05%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.16% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. AMF Tjanstepension AB grew its position in Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth about $209,000. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $213,000. Swedbank AB raised its holdings in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after acquiring an additional 111,570 shares in the last quarter. Finally, Tempus Wealth Planning LLC grew its position in Johnson & Johnson by 3.9% in the 3rd quarter. Tempus Wealth Planning LLC now owns 8,808 shares of the company’s stock valued at $1,427,000 after acquiring an additional 328 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Ride Out The Recession With These Dividend Kings
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Health Care Stocks Explained: Why You Might Want to Invest
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- What is the S&P 500 and How It is Distinct from Other Indexes
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.